FIGURE 3.
Sera of COVID‐19 convalescent patients recognize less mutated RBD (RBDTRIP, RBDN501Y, RBDE484K, and RBDK417N). A) Binding of sera from 12 COVID‐19 convalescent patients and one COVID negative individual to RBDWT and mutated RBDs was determined by ELISA. Endpoint titers (EPT; dilution factor) individuals are shown as dots. Direct binding of sera to RBDWT and mutated RBDs (B) and competitive inhibition of ACE2‐mFc interaction to RBDWT and mutated RBD (C) were assessed by BLI. The same sera (dilution 1:20) for each individual were usual. p ≤ .05 (*), p ≤ .01 (**), p ≤ .005 (***), and p ≤ .001 (****)